Gaining Insights into Islatravir and Doravirine
Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.
As the virtual AIDS 2020 Conference kicked off today, a number of studies and data were released to the public. As such, Contagion® will be covering important studies, discussions and other aspects of the virtual conference.
For example, Merck released new data today from its Phase 2b trial regarding islatravir, the company’s investigational oral nucleoside reverse transcriptase translocation inhibitor in combination with doravirine in adults with HIV who had not previously received antiretroviral treatment.
Results included the tolerability and safety profile of islatravir in combination with doravirine (100 mg) through week 48 across three dose levels including 0.25, 0.75, and 2.25 mg.
Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.
Hwang also spoke about unmet needs including the current HIV population and the unique challenges behind this aging patient group.
In addition, he spoke of medical research continuing despite the coronavirus 2019 (COVID-19).
